Oxford Biomedica PLC

AGM Information • May 28, 2021

National Storage Mechanism | Additional information

RNS Number : 1127A

Oxford Biomedica PLC

28 May 2021

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 28 May 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2021 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2021 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (25 May 2021) there were 82,543,197 ordinary shares of 50 pence each in issue, each carrying one vote per share.

	Resolution	Votes For	Votes at Chairman's Discretion	Votes at other proxy Discretion	Votes Against	Votes Withheld*	Total votes cast	Result
	Ordinary resolutions
1	To receive the Company's  Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2020	58,334,279 (99.99%)	8,574 (0.01%)	0	1,440 (0.00%)	59,353	58,344,293	Passed
2	To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2020	57,033,865 (98.72%)	8,574 (0.01%)	0	731,131 (1.27%)	630,076	57,773,570	Passed
3	To approve the Directors' Remuneration Policy	46,429,406 (80.94%)	8,574 (0.01%)	0	10,926,461 (19.05%)	1,039,205	57,364,441	Passed
4	To appoint Dr. Roch Doliveux as a Director.	57,832,864 (99.04%)	8,574   (0.01%)	0	554,706 (0.95%)	7,502	58,396,144	Passed
5	To appoint Professor Dame Kay Davies as a Director	58,385,668  (99.99)	8,574 (0.01%)	0	1,640 (0.00%)	7,764	58,395,882	Passed
6	To appoint Dr. Siyamak Rasty as a Director	58,325,223  (99.88%)	8,574   (0.01%)	0	62,347  (0.11%)	7,502	58,396,144	Passed
7	To reappoint John Dawson as a Director	58,194,899  (99.66%)	8,574  (0.01%)	0	192,871  (0.33%)	7,302	58,396,344	Passed
8	To reappoint Stuart Paynter as a Director	58,195,041  (99.66%)	8,574   (0.01%)	0	192,729   (0.33%)	7,302	58,396,344	Passed
9	To reappoint Stuart Henderson as a Director	55,957,927  (95.84%)	8,574   (0.01%)	0	2,423,167   (4.15%)	13,978	58,389,668	Passed
10	To reappoint Dr. Heather Preston as a Director	55,966,994  (95.84%)	8,574   (0.01%)	0	2,421,352   (4.15%)	6,726	58,396,920	Passed
11	To reappoint Robert Ghenchev as a Director	58,193,434  (99.66%)	8,574   (0.01%)	0	194,336   (0.33%)	7,302	58,396,344	Passed
12	To reappoint KMPG LLP as auditor	58,376,747  (99.98%)	8,674   (0.01%)	0	6,633   (0.01%)	11,592	58,392,054	Passed
13	To authorise the Directors to agree the remuneration of the auditor	57,756,307  (99.98%)	8,574   (0.01%)	0	5,556   (0.01%)	633,209	57,770,437	Passed
14	To amend the rules of the Oxford Biomedica 2015 Long Term Incentive Plan	46,776,691  (81.55%)	8,574   (0.01%)	0	10,579,473  (18.44%)	1,038,908	57,364,738	Passed
15	To amend the rules of the Oxford Biomedica 2015 Executive Share Option Scheme	46,773,232  (81.54%)	8,574   (0.01%)	0	10,582,625  (18.45%)	10,582,625  (18.45%)	57,364,431	Passed
16	To authorise the Directors to allot shares	55,826,926  (96.64%)	8,574   (0.01%)	0	1,936,496   (3.35%)	631,650	57,771,996	Passed
	Special resolutions
17	To authorise the Directors to disapplypre-emption rights	57,477,832  (99.49%)	8,574   (0.01%)	0	286,354   (0.50%)	630,886	57,772,760	Passed
18	To authorise the Directors to further disapply pre-emption rights foracquisitions and specified capital investments	57,477,350  (99.49%)	8,574   (0.01%)	0	286,636   (0.50%)	631,086	57,772,560	Passed
19	To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice	56,393,012  (96.57%)	8,574   (0.01%)	0	1,996,782   (3.42%)	5,278	58,398,368	Passed

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

-Ends-

Enquiries:
Oxford Biomedica plc John Dawson, Chief Executive Officer Stuart Paynter, Chief Financial Officer Catherine Isted, Head of Corporate Development & IR	T: +44 (0)1865 783 000 T: +44 (0)1865 783 000 T: +44 (0)1865 954 161 / E: ir@oxb.com
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	T: +44 (0)20 3709 5700

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSEDESWEFSELI